Association of genetic polymorphisms of CYP2E1, NAT2, GST and SLCO1B1 with the risk of anti-tuberculosis drug-induced liver injury: a systematic review and meta-analysis. Issue 8 (1st August 2019)

• Record Type: Journal Article
• Authors: Yang, Seungwon; Hwang, Se Jung; Park, Jung Yun; Chung, Eun Kyoung; Lee, Jangik I
• Is Part Of: BMJ open. Volume 9:Issue 8(2019)
• Publication Date: 2019-08-01
• Subjects: anti-tuberculosis drug-induced liver injury -- genetic polymorphisms -- meta-analysis -- drug-metabolizing enzyme -- drug transporter -- tuberculosis; Medicine -- Research -- Periodicals; 610.72
• DOI: 10.1136/bmjopen-2018-027940
• Languages: English
• ISSNs: 2044-6055

Abstract

Abstract : Objectives: The objective of this study was to investigate the association between genetic polymorphisms of N-acetyltransferase 2 ( NAT2), cytochrome P450 2E1 ( CYP2E1), glutathione S-transferase ( GST) and solute carrier organic anion transporter family member 1B1 ( SLCO1B1) and the risk of anti-tuberculosis drug-induced liver injury (ATDILI). Design: Systematic review and meta-analysis. Data sources: PubMed, Embase, Web of Science and Cochrane Reviews databases were searched through April 2019. Eligibility criteria: We included case-control or cohort studies investigating an association between NAT2, CYP2E1, GST or SLCO1B1 polymorphisms and the ATDILI risk in patients with tuberculosis. Data extraction and synthesis: Three authors screened articles, extracted data and assessed study quality. The strength of association was evaluated for each gene using the pooled OR with a 95% CI based on the fixed-effects or random-effects model. Sensitivity analysis was performed to confirm the reliability and robustness of the results. Results: Fifty-four studies were included in this analysis (n=26 for CYP2E1, n=35 for NAT2, n=19 for GST, n=4 for SLCO1B1 ). The risk of ATDILI was significantly increased with the following genotypes: CYP2E1 Rsa I /Pst I c1/c1 (OR=1.39, 95% CI 1.06 to 1.83), NAT2 slow acetylator (OR=3.30, 95% CI 2.65 to 4.11) and GSTM1 null (OR=1.30, 95% CI 1.12 to 1.52). No significant association with ATDILI was found for the genetic polymorphisms of CYP2E1 Dra I, GSTT1, GSTM1/GSTT1, SLCO1B1 388A>G and SLCO1B1 521T>C (p>0.05). Conclusions: ATDILI is more likely to occur in patients with NAT2 slow acetylator genotype, CYP2E1 RsaI/PstI c1/c1 genotype and GSTM1 null genotype. Close monitoring may be warranted for patients with these genotypes.